Mayor Erythropoietic Response after Deferasirox Treatment in a Transfusion-Dependent Anemic Patient with Primary Myelofibrosis

Primary myelofibrosis (PMF) is a myeloproliferative neoplasm frequently complicated by transfusion dependent anemia. Both anemia and transfusion-dependence are associated with a poor outcome, at least in part because of toxic effects of iron overload (IOL). Iron-chelating therapy (ICT) is increasing...

Descripción completa

Detalles Bibliográficos
Autores principales: Lisette, Del Corso, Enrico, Balleari, Eleonora, Arboscello, Riccardo, Ghio, Manlio, Mencoboni, Omar, Racchi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3836304/
https://www.ncbi.nlm.nih.gov/pubmed/24307957
http://dx.doi.org/10.1155/2013/520712
_version_ 1782292291170336768
author Lisette, Del Corso
Enrico, Balleari
Eleonora, Arboscello
Riccardo, Ghio
Manlio, Mencoboni
Omar, Racchi
author_facet Lisette, Del Corso
Enrico, Balleari
Eleonora, Arboscello
Riccardo, Ghio
Manlio, Mencoboni
Omar, Racchi
author_sort Lisette, Del Corso
collection PubMed
description Primary myelofibrosis (PMF) is a myeloproliferative neoplasm frequently complicated by transfusion dependent anemia. Both anemia and transfusion-dependence are associated with a poor outcome, at least in part because of toxic effects of iron overload (IOL). Iron-chelating therapy (ICT) is increasingly used in order to prevent IOL in this setting. Here, we describe the case of a 73-year-old man affected by PMF and severe transfusion-dependent anemia who experienced a dramatic erythroid response after being treated with deferasirox to prevent IOL.
format Online
Article
Text
id pubmed-3836304
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-38363042013-12-04 Mayor Erythropoietic Response after Deferasirox Treatment in a Transfusion-Dependent Anemic Patient with Primary Myelofibrosis Lisette, Del Corso Enrico, Balleari Eleonora, Arboscello Riccardo, Ghio Manlio, Mencoboni Omar, Racchi Case Rep Hematol Case Report Primary myelofibrosis (PMF) is a myeloproliferative neoplasm frequently complicated by transfusion dependent anemia. Both anemia and transfusion-dependence are associated with a poor outcome, at least in part because of toxic effects of iron overload (IOL). Iron-chelating therapy (ICT) is increasingly used in order to prevent IOL in this setting. Here, we describe the case of a 73-year-old man affected by PMF and severe transfusion-dependent anemia who experienced a dramatic erythroid response after being treated with deferasirox to prevent IOL. Hindawi Publishing Corporation 2013 2013-11-06 /pmc/articles/PMC3836304/ /pubmed/24307957 http://dx.doi.org/10.1155/2013/520712 Text en Copyright © 2013 Del Corso Lisette et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Lisette, Del Corso
Enrico, Balleari
Eleonora, Arboscello
Riccardo, Ghio
Manlio, Mencoboni
Omar, Racchi
Mayor Erythropoietic Response after Deferasirox Treatment in a Transfusion-Dependent Anemic Patient with Primary Myelofibrosis
title Mayor Erythropoietic Response after Deferasirox Treatment in a Transfusion-Dependent Anemic Patient with Primary Myelofibrosis
title_full Mayor Erythropoietic Response after Deferasirox Treatment in a Transfusion-Dependent Anemic Patient with Primary Myelofibrosis
title_fullStr Mayor Erythropoietic Response after Deferasirox Treatment in a Transfusion-Dependent Anemic Patient with Primary Myelofibrosis
title_full_unstemmed Mayor Erythropoietic Response after Deferasirox Treatment in a Transfusion-Dependent Anemic Patient with Primary Myelofibrosis
title_short Mayor Erythropoietic Response after Deferasirox Treatment in a Transfusion-Dependent Anemic Patient with Primary Myelofibrosis
title_sort mayor erythropoietic response after deferasirox treatment in a transfusion-dependent anemic patient with primary myelofibrosis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3836304/
https://www.ncbi.nlm.nih.gov/pubmed/24307957
http://dx.doi.org/10.1155/2013/520712
work_keys_str_mv AT lisettedelcorso mayorerythropoieticresponseafterdeferasiroxtreatmentinatransfusiondependentanemicpatientwithprimarymyelofibrosis
AT enricoballeari mayorerythropoieticresponseafterdeferasiroxtreatmentinatransfusiondependentanemicpatientwithprimarymyelofibrosis
AT eleonoraarboscello mayorerythropoieticresponseafterdeferasiroxtreatmentinatransfusiondependentanemicpatientwithprimarymyelofibrosis
AT riccardoghio mayorerythropoieticresponseafterdeferasiroxtreatmentinatransfusiondependentanemicpatientwithprimarymyelofibrosis
AT manliomencoboni mayorerythropoieticresponseafterdeferasiroxtreatmentinatransfusiondependentanemicpatientwithprimarymyelofibrosis
AT omarracchi mayorerythropoieticresponseafterdeferasiroxtreatmentinatransfusiondependentanemicpatientwithprimarymyelofibrosis

Ejemplares similares